Associations between pretreatment characteristics and achievement of CR and MRD-negativity
| Characteristics n = 300 unless stated . | CR n (%) . | P . | MRD-negative . | P . |
|---|---|---|---|---|
| Age, median (range); 57 y (17-86 y) | ||||
| Age category | ||||
| Age <65, n = 228 | 173 (75.9) | |||
| Age 65-74, n = 61 | 42 (68.9) | 104/239 (43.5) | ||
| Age ≥75, n = 11 | 4 (36.4) | .011 | 2/7 (28.6) | .43 |
| B2M (mg/L), n = 296 | ||||
| <4.0, n = 168 | 143 (85.1) | 69/141 (48.9) | ||
| ≥4.0, n = 128 | 73 (57.0) | <.001 | 35/101 (34.7) | .027 |
| Gender | ||||
| Male, n = 211 | 155 (70.8) | 63/173 (36.4) | ||
| Female, n = 89 | 64 (71.9) | .782 | 43/73 (58.9) | .001 |
| ECOG PS | ||||
| 0, n = 119 | 96 (80.7) | 43/95 (45.3) | ||
| 1, n = 171 | 118 (69.0) | 60/143 (42.0) | ||
| 2, n = 10 | 5 (50.0) | .022 | 3/5 (37.5) | .84 |
| IGHV mutation status, n = 214 | ||||
| Mutated, n = 88 | 73 (83.0) | 35/69 (50.7) | ||
| Unmutated, n = 126 | 91 (72.2) | .068 | 35/106 (33.0) | .019 |
| Rai stage | ||||
| 0-II,* n = 193 | 147 (76.2) | 76/165 (46.1) | ||
| III-IV, n = 107 | 72 (67.3) | .097 | 30/81 (37.0) | .18 |
| WCC (×109/L) | ||||
| <200, n = 273 | 207 (75.8) | 100/221 (45.1) | ||
| ≥200, n = 27 | 12 (44.4) | <.001 | 6/25 (24.0) | .042 |
| LDH | ||||
| Normal, n = 192 | 145 (75.5) | 69/157 (43.9) | ||
| > Normal, n = 108 | 74 (68.5) | .190 | 37/89 (41.6) | .72 |
| ZAP70 by IHC, n = 209 | ||||
| Negative, n = 83 | 63 (75.9) | 34/66 (51.5) | ||
| Positive, n = 126 | 95 (75.4) | .933 | 39/102 (38.2) | .09 |
| Del(17p) by karyotyping, n = 222 | ||||
| Del(17p), n = 5 | 1 (20.0) | 0/4 (0) | ||
| No del(17p), n = 217 | 163 (75.1) | .006 | 77/175 (44.0) | .079 |
| Number of cycles received | ||||
| 1-3, n = 33 | 10 (30.3) | 2/19 (10.5) | ||
| 4-5, n = 44 | 28 (63.6) | 12/31 (38.7) | ||
| 6, n = 223 | 181 (81.2) | <.001 | 92/196 (46.9) | .008 |
| Characteristics n = 300 unless stated . | CR n (%) . | P . | MRD-negative . | P . |
|---|---|---|---|---|
| Age, median (range); 57 y (17-86 y) | ||||
| Age category | ||||
| Age <65, n = 228 | 173 (75.9) | |||
| Age 65-74, n = 61 | 42 (68.9) | 104/239 (43.5) | ||
| Age ≥75, n = 11 | 4 (36.4) | .011 | 2/7 (28.6) | .43 |
| B2M (mg/L), n = 296 | ||||
| <4.0, n = 168 | 143 (85.1) | 69/141 (48.9) | ||
| ≥4.0, n = 128 | 73 (57.0) | <.001 | 35/101 (34.7) | .027 |
| Gender | ||||
| Male, n = 211 | 155 (70.8) | 63/173 (36.4) | ||
| Female, n = 89 | 64 (71.9) | .782 | 43/73 (58.9) | .001 |
| ECOG PS | ||||
| 0, n = 119 | 96 (80.7) | 43/95 (45.3) | ||
| 1, n = 171 | 118 (69.0) | 60/143 (42.0) | ||
| 2, n = 10 | 5 (50.0) | .022 | 3/5 (37.5) | .84 |
| IGHV mutation status, n = 214 | ||||
| Mutated, n = 88 | 73 (83.0) | 35/69 (50.7) | ||
| Unmutated, n = 126 | 91 (72.2) | .068 | 35/106 (33.0) | .019 |
| Rai stage | ||||
| 0-II,* n = 193 | 147 (76.2) | 76/165 (46.1) | ||
| III-IV, n = 107 | 72 (67.3) | .097 | 30/81 (37.0) | .18 |
| WCC (×109/L) | ||||
| <200, n = 273 | 207 (75.8) | 100/221 (45.1) | ||
| ≥200, n = 27 | 12 (44.4) | <.001 | 6/25 (24.0) | .042 |
| LDH | ||||
| Normal, n = 192 | 145 (75.5) | 69/157 (43.9) | ||
| > Normal, n = 108 | 74 (68.5) | .190 | 37/89 (41.6) | .72 |
| ZAP70 by IHC, n = 209 | ||||
| Negative, n = 83 | 63 (75.9) | 34/66 (51.5) | ||
| Positive, n = 126 | 95 (75.4) | .933 | 39/102 (38.2) | .09 |
| Del(17p) by karyotyping, n = 222 | ||||
| Del(17p), n = 5 | 1 (20.0) | 0/4 (0) | ||
| No del(17p), n = 217 | 163 (75.1) | .006 | 77/175 (44.0) | .079 |
| Number of cycles received | ||||
| 1-3, n = 33 | 10 (30.3) | 2/19 (10.5) | ||
| 4-5, n = 44 | 28 (63.6) | 12/31 (38.7) | ||
| 6, n = 223 | 181 (81.2) | <.001 | 92/196 (46.9) | .008 |
A total of 11 patients had Rai stage 0 disease and were treated due to disease-associated symptoms.